

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Klaus Bosslet et al.

Examiner: **Fetterolf, Brandon J**

Application No.: **10/815,925**

Art Unit: **1642**

Filed: **April 02, 2004**

Title: **BIFUNCTIONAL GLYCOPROTEINS HAVING A MODIFIED CARBOHYDRATE
COMPLEMENT AND THEIR USE IN TUMOR-SELECTIVE THERAPY**

RESPONSE TO OFFICE COMMUNICATION

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Restriction Requirement under 35 U.S.C. § 121 dated November 29, 2006, Applicants provisionally elect Group I (Claims 1-5, 7, and 9-18), "as specifically drawn to a compound comprising a bifunctional fusion glycoprotein or bifunctional glycoprotein conjugate, the compound comprising a carbohydrate complement, and: a) a first portion which is an enzyme; b) a second portion which binds specifically to an epitope of a tumor specific antigen; wherein the carbohydrate complement comprises at least one exposed terminal carbohydrate residue, classified in class 530, subclass 350", *with traverse*. To comply with the Examiner's Election of Species Requirement, Applicants also provisionally elect β -glucuronidase for Claim 7 of Group I and anti CEA for Claim 9 of Groups I and II.

Applicants respectfully request reconsideration and modification of the restriction requirement in view of the following remarks.